Our Drug Development Pipeline
Drug Development Pipeline
kt-2000AI
Deep Docking™: AI Driven Discovery of Best-in-Class Cancer Therapies
Beyond the success of PARP inhibitors, the field of DNA-damage response inhibition has unveiled a wealth of promising targets for cancer treatment.
The emergence of new targets provides a rich landscape of potential strategies poised to revolutionize the treatment of cancer.
kt-5000AI
ENKI™: AI-Designed CNS-Penetrant ATR Inhibitors
Rakovina Therapeutics’ kt-5000AI series is a novel class of small-molecule drug candidates designed to inhibit ATR with CNS penetration. ATR regulates DNA damage repair, and PTEN-loss cancers may be especially vulnerable to ATR inhibition.
kt-3000 series
Rakovina Therapeutics’ kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly(ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule.
This novel approach has the potential to overcome treatment resistance and provide meaningful clinical benefit to cancer patients.
